However, for cancer patients with malignant tumors with SMARCA4 alterations, more downstream targets need to be demonstrated, which have been used in conjunction with their clinical coadministration, an approach that has a more long-term therapeutic outlook for the treatment of cancer. Here, SMARCA4 is linked to cancer.